Biowaiver

In vivo bioavailability and/or bioequivalence investigations may be waived with a Biowaiver (not considered necessary for product approval). A dissolution test could be used as a surrogate basis for determining whether two medicinal items are equal instead of expensive and time-consuming in vivo trials. At the time, the Biowaiver was only used for pharmaceutical scale-up and post-approval adjustments (SUPAC).

  • High Solubility. High Permeability
  • Low solubility. High Permeability
  • High Solubility. Low Permeability
  • Low Solubility. Low Permeability

Related Conference of Biowaiver

April 14-15, 2025

18th European Biosimilars Congress

Paris, France
April 14-15, 2025

35th Annual European Pharma Congress

Paris, France
April 24-25, 2025

18th World Drug Delivery Summit

London, UK
May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Paris, France
August 18-19, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
September 22-23, 2025

Pharma Biotech Expo

Toronto, Canada
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

13th International Conference on Clinical Trials

Amsterdam, Netherlands

Biowaiver Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in